Sarepta Therapeutics (SRPT) Tax Provisions (2017 - 2026)

Sarepta Therapeutics' Tax Provisions history runs 10 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• On a quarterly basis, Tax Provisions fell 80.94% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was -$40.6 million, a 148.09% decrease from a year earlier, with the FY2025 full-year figure at $11.2 million, down 56.62% from the prior year.
• Tax Provisions advanced to $12.2 million in Q1 2026 per SRPT's latest filing, from $4.6 million in the prior quarter.
• Across five years, Tax Provisions topped out at $64.0 million in Q1 2025 and bottomed at -$43.3 million in Q2 2025.
• The 5-year median for Tax Provisions is $4.6 million (2025), against an average of $4.6 million.
• Across the five-year window, Tax Provisions surged 1879.55% in 2022 and tumbled 3670.13% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $7.9 million in 2022, then sank by 164.49% to -$5.1 million in 2023, then jumped by 352.84% to $12.9 million in 2024, then sank by 64.58% to $4.6 million in 2025, then surged by 166.09% to $12.2 million in 2026.
• Per Business Quant, the three latest SRPT Tax Provisions figures stand at $12.2 million (Q1 2026), $4.6 million (Q4 2025), and -$14.1 million (Q3 2025).